Steroid Strategies in Diabetic Macular Edema - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Steroid Strategies in Diabetic Macular Edema

  • By

  • Ashish Sharma, MD

  • Baruch D. Kuppermann, MD, PhD

  • May 1, 2026

  • 13 min

Share

Clinical Scorecard: Steroid Strategies in Diabetic Macular Edema

At a Glance

CategoryDetail
ConditionDiabetic Macular Edema (DME)
Key MechanismsInvolves VEGF-mediated vascular permeability and chronic inflammation.
Target PopulationPatients with diabetic macular edema, particularly those with inadequate response to anti-VEGF therapy.
Care SettingOphthalmology clinics and practices managing diabetic eye diseases.

Key Highlights

  • Corticosteroids provide a broader anti-inflammatory effect compared to anti-VEGF agents.
  • Patient selection is critical to optimize outcomes and minimize adverse effects.
  • Intravitreal corticosteroids can improve adherence due to reduced injection frequency.
  • Emerging OCT biomarkers may predict response to steroid therapy.
  • Corticosteroids target multiple inflammatory pathways contributing to DME.

Guideline-Based Recommendations

Diagnosis

  • Utilize OCT biomarkers to assess inflammatory activity in DME.

Management

  • Consider corticosteroids for chronic, refractory, or inflammation-driven DME.

Monitoring & Follow-up

  • Regularly assess visual acuity and retinal anatomy post-treatment.

Risks

  • Monitor for intraocular pressure elevation and cataract progression in steroid responders.

Patient & Prescribing Data

Patients with diabetic macular edema, especially those unresponsive to anti-VEGF therapy.

Triamcinolone (2-4 mg) offers short-term relief; dexamethasone implants provide sustained delivery for 3-4 months.

Clinical Best Practices

  • Tailor corticosteroid therapy based on ocular characteristics and prior treatment responses.
  • Assess glaucoma risk before initiating corticosteroid treatment.
  • Utilize a multidisciplinary approach for managing DME, integrating both anti-VEGF and corticosteroid therapies.

Related Resources & Content

Original Source(s)

Steroid Strategies in Diabetic Macular Edema

  • by Ashish Sharma, MD, Baruch D. Kuppermann, MD, PhD

  • May 1, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Fellowship-Trained Neuro-Oncologist Nishika Karbhari, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute

Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute.

  • by

  • September 3, 2026

  • 2 min
Therapy-induced immunoediting and the evolution of cancer immune escape